This is a Phase 3, open-label, uncontrolled, extension study to assess the long-term efficacy and safety of lesinurad monotherapy in subjects who completed the double-blind treatment period in Study RDEA594-303.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01650246?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
